SCHEMBL1629969

SCHEMBL1629969

CCC(C)OP(=O)(O)c1ccc(C(N)=O)cc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 1/20 0.36
PARP10 Q53GL7 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
RAB9A P51151 1/20 0.35
CREBBP Q92793 1/20 0.34
LMNA P02545 2/20 0.33
MMP2 P08253 1/20 0.32
MMP13 P45452 1/20 0.32
CA2 P00918 2/20 0.32
CA1 P00915 1/20 0.32
TSHR P16473 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
HTR1A P08908 1/20 0.32
HTR1D P28221 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631592 0.91 MAPK1 (0.37) HSD17B10KDM4EALDH1A1MAPK1PARP10
SCHEMBL1630150 0.82 DPP8 (0.36) HSD17B10ALDH1A1SMN1; SMN2CA1THRB
SCHEMBL641442 0.77 ALDH1A1 (0.35) HSD17B10KDM4EALDH1A1TSHRMAPT
SCHEMBL1629454 0.75 ALOX5 (0.34) HSD17B10KDM4EALDH1A1USP2MEN1
SCHEMBL1631356 0.74 ALOX15 (0.34) HSD17B10ALDH1A1SMN1; SMN2TSHRTHRB
SCHEMBL1632841 0.74 IRAK4 (0.36) HSD17B10KDM4EALDH1A1LMNATSHR
SCHEMBL1629966 0.73 POLB (0.43) HSD17B10KDM4EALDH1A1MAPK1PARP10
SCHEMBL4023643 0.73 DPP8 (0.34) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL1629974 0.73 ALDH1A1 (0.36) KDM4EALDH1A1SMN1; SMN2RAB9ALMNA
SCHEMBL11587963 0.72 HSD17B10 (0.42) HSD17B10KDM4EALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183260-B1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS INC (US) 2011-06-01 EP disclosed
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
EP-2183260-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
WO-2009032180-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV POLI, ITPA, POLR2H HSD17B10 1448/4885KDM4E 2096/4885ALDH1A1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.